The most common peripheral nervous system manifestations in Sjogren’s syndrome are small fiber sensory neuropathies (SFPN) and axonal sensorimotor polyneuropathies. Currently, treatment in small fiber neuropathy is mainly symptomatic and based on anti-depressors and anti-epileptics. The benefit of treatment with polyvalent immunoglobulins for SFPN has been reported in small series of patients, although transient in several cases. The medium-to-long-term effects of polyvalent immunoglobulins (Ig) in SFPN in patients with Sjogren’s syndrome who are refractory to conventional treatments remain an unmet medical need. We present our experience related to the persistent improvement of Ig in a case series of SFPN in Sjogren’s syndrome and relevant data in the literature regarding the benefits of immunoglobulins, for this indication.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Binard A, Devauchelle-Pensec V, Fautrel B, Jousse S, Youinou P, Saraux A (2007) Epidemiology of Sjögren's syndrome: where are we now? Clin Exp Rheumatol 25:1–4
Segal B, Thomas W, Rogers T et al (2008) Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren's syndrome. Arthritis Rheum 59:1780–1787
Ramos-Casals M, Solans R, Rosas J, GEMESS Study Group et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 87:210–219
Pavlakis PP, Alexopoulos H, Kosmidis ML et al (2011) Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry 82:798–802
Mori K, Iijima M, Koike H et al (2005) The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy. Brain 128:2518–2534
Delalande S, de Seze J, Fauchais AL et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine 83:280–291
Devigili G, Tugnoli V, Penza P et al (2008) The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 131:1912–1925
Gorson KC, Ropper AH (1995) Idiopathic distal small fiber neuropathy. Acta Neurol Scand 92:376–382
De Sousa EA, Hays AP, Chin RL, Sander HW, Brannagan TH (2006) Characteristics of patients with sensory neuropathy diagnosed with abnormal small nerve fibres on skin biopsy. J Neurol Neurosurg Psychiatry 77:983–985
Chai J, Herrmann DN, Stanton M, Barbano RL, Logigian EL (2005) Painful small-fiber neuropathy in Sjogren syndrome. Neurology 65:925–927
Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, Waxman SG (2012) Small-fibre neuropathies—advances in diagnosis, pathophysiology and management. Nat Rev Neurol 8:369–379
Oaklander AL, Klein MM (2013) Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes. Pediatrics 131:e1091–e1100
Lang M, Treister R, Oaklander AL (2016) Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy. J Neurol 263:2515–2527
Moulin D, Boulanger A, Clark AJ, Canadian Pain Society et al (2014) Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 19:328–335
Gorson KC, Herrmann DN, Thiagarajan R et al (2008) Non-length dependent small fibre neuropathy/ganglionopathy. J Neurol Neurosurg Psychiatry 79:163–169
Dabby R, Gilad R, Sadeh M, Lampl Y, Watemberg N (2006) Acute steroid responsive small-fiber sensory neuropathy: a new entity? J Peripher Nerv Syst 11:47–52
Sève P, Gachon E, Petiot P, Stankovic K, Charhon A, Broussolle C (2007) Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren's syndrome. Rheumatol Int 28:175–177
Mekinian A, Ravaud P, Hatron PY et al (2012) Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 71:84–87
Wakasugi D, Kato T, Gono T et al (2009) Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren's syndrome. Mod Rheumatol 19:437–440
Morozumi S, Kawagashira Y, Iijima M et al (2009) Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome. J Neurol Sci 279:57–61
Molina JA, Benito-León J, Bermejo F, Jiménez-Jiménez FJ, Oliván J (1996) Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren's syndrome. J Neurol Neurosurg Psychiatry 60:699
Kizawa M, Mori K, Iijima M, Koike H, Hattori N, Sobue G (2006) Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren's syndrome. J Neurol Neurosurg Psychiatry 77:967–969
Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367–2375
Vitali C, Bombardieri S, Jonsson R, European Study Group on Classification Criteria for Sjögren's Syndrome et al (2002) Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558
Lauria G, Hsieh ST, Johansson O, Kennedy WR et al (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the Use of Skin Biopsy in the Diagnosis of Small Fiber Neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 17(7):903–912
Souayah N, Chin RL, Brannagan TH et al (2008) Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol 15:1300–1303
Parambil JG, Tavee JO, Zhou L, Pearson KS, Culver DA (2011) Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 105:101–105
Hughes RA, Donofrio P, Bril V, ICE Study Group et al (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136–144
Léger JM, De Bleecker JL, Sommer C, PRIMA study investigators et al (2013) Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). J Peripher Nerv Syst. 18:130–140
Kubori T, Mezaki T, Kaji R et al (1999) The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy]. No To Shinkei 51:127–135
van Schaik IN, Bril V, van Geloven N, PATH Study Group et al (2018) Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17:35–46
Mahdi-Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA (2017) Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 5:CD003280
van der Meche FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123–1129
Hughes RA (1996) Intravenous IgG in Guillain-Barré syndrome. BMJ 313:376–377
Pereira PR, Viala K, Maisonobe T et al (2016) Sjögren sensory neuronopathy (Sjögren Ganglionopathy): long-term outcome and treatment response in a series of 13 cases. Medicine 95:e3632
Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I (2003) Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren’s syndrome. IV immunoglobulin. Neurology 60:503–505
Rist S, Sellam J, Hachulla E et al (2011) Club Rhumatismes et inflammation. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken) 63:1339–1344
Birnbaum J (2010) Peripheral nervous system manifestations of Sjogren syndrome: clinical patterns, diagnostic paradigms, etiopathogenesis, and therapeutic strategies. Neurologist 16:287–297
Liu X, Treister T, Lang M, Oaklander AL (2018) IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. Ther Adv Neurol Disord 11:1756285617744484
de Greef BT, Geerts M, Hoeijmakers JG, Faber CG, Merkies IS (2016) Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial. Trials 17:330
Kuitwaard K, van den Berg LH, Vermeulen M et al (2010) Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 81:1374–1379
Rajabally YA, Kearney DA (2011) Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci 308:124–127
Mohamed M (2016) Intravenous immunoglobulin-associated hemolysis: risk factors, challenges, and solutions. Int J Clin Transfus Med 4:121–131
van Schaik IN, van den Berg LH, de Haan R, Vermeulen M (2005) Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 18:CD004429
Rajabally YA, Seow H, Wilson P (2006) Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 11:325–329
Lunn MP, Ellis L, Hadden RD, Rajabally YA, Winer JB, Reilly MM (2016) A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst 21:33–37
Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA (2018) A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. J Peripher Nerv Syst 23:108–114
Oaklander AL, Lang M, Treister R, Liu X (2015) First evaluation of immunoglobulin treatment of small-fiber axonal polyneuropathy (SFPN). Ann Neurol 78:S109
Cherin P, Belizna C, Cartry O et al (2016) Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases. Autoimmun Rev 15:281–286
Cocito D, Merola A, Peci E et al (2014) SCIg and chronic dysimmune neuropathies Italian Network. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. J Neurol. 261:2159–2164
Racosta JM, Sposato LA, Kimpinski K (2017) Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis. Muscle Nerve 55:802–809
The authors have no financial relationships relevant to this article to disclose.
Conflicts of interest
The study is not industry sponsored. Dr. Pindi Sala reports no disclosures. Mrs Mona Villedieu reports no disclosures. Dr Laura Damian reports no disclosures. Mr Jean-Charles Crave reports no disclosures. Dr Vivien Pautot reports no disclosures. Professor Ljudmila Stojanovich reports no disclosures. Professor Jan Willem Cohen Tervaert reports no disclosures. Professor Patrick Cherin reports no disclosures. Dr. Cristina Belizna reports no disclosures.
No ethics committee approval was required for this report.
Consent for publication
As per local legislation, patients were informed that data from their treatment may be reported and did not refuse the anonymous dissemination of this information.
All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
|Taylor Pindi Sala||University Paris Diderot, EA 7334, Patient Centered Outcomes Research, Paris, France||Conceptualized and designed the study, collected data, and reviewed and revised the manuscript for important intellectual content|
|Mona Villedieu||Octapharma, 92,100 Boulogne Billancourt, France||Conceptualized and designed the study, collected data, and reviewed and revised the manuscript for important intellectual content|
|Jean-Charles Crave||Octapharma, 92,100 Boulogne Billancourt, France||Conceptualized and designed the study, collected data, and reviewed and revised the manuscript for important intellectual content|
|Laura Damian||Department of Rheumatology, County Emergency Hospital Cluj-Napoca, Cluj-Napoca, Romania|
|Vivien Pautot||Department of Neurology University Hospital Angers, Angers, France|
|Ljudmila Stojanovich||Scientific Research Department, Internal Medicine-Rheumatology Bezhanijska Kosa, University Medical Center, Belgrade University, Serbia|
|Jan Willem Cohen Tervaert||Department of Medicine, Division of Rheumatology University of Alberta, Edmonton, AB, Canada|
|Patrick Cherin||Internal Medicine Department Hôpital Pitié-Salpétrière, 75,013 Paris||Coordinated and conceptualized and designated the study and critically reviewed the manuscript for important intellectual content|
Vascular and Coagulation Department, University Hospital Angers, Angers, France|
CNRS 6015 INSERMU1083, UMR, Angers, France
|Coordinated and conceptualized and designated the study and critically reviewed the manuscript for important intellectual content|
About this article
Cite this article
Pindi Sala, T., Villedieu, M., Damian, L. et al. Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjögren’s syndrome. J Neurol 267, 3499–3507 (2020). https://doi.org/10.1007/s00415-020-10033-z
- Small fiber sensory neuropathies and sjögren syndrome
- Small fiber sensory neuropathies and sjögren syndrome and treatment
- Small fiber sensory neuropathies in sjögren syndrome and immunoglobulins
- Small fiber sensory neuropathies in sjögren syndrome and intravenous immunoglobulins
- Small fiber sensory neuropathies in sjögren syndrome and subcutaneous immunoglobulins